Compare LMND & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LMND | CRNX |
|---|---|---|
| Founded | 2015 | 2008 |
| Country | United States | United States |
| Employees | 1282 | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.9B |
| IPO Year | N/A | 2018 |
| Metric | LMND | CRNX |
|---|---|---|
| Price | $62.45 | $36.54 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 9 |
| Target Price | $64.75 | ★ $74.78 |
| AVG Volume (30 Days) | ★ 1.9M | 1.1M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,039,000.00 |
| Revenue This Year | $64.93 | $722.66 |
| Revenue Next Year | $32.87 | $183.79 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $24.31 | $24.10 |
| 52 Week High | $99.90 | $57.99 |
| Indicator | LMND | CRNX |
|---|---|---|
| Relative Strength Index (RSI) | 50.49 | 43.63 |
| Support Level | $49.09 | $33.23 |
| Resistance Level | $69.30 | $37.23 |
| Average True Range (ATR) | 3.55 | 1.69 |
| MACD | 0.57 | 0.28 |
| Stochastic Oscillator | 60.74 | 64.01 |
Lemonade Inc operates in the insurance industry. The company offers digital and artificial intelligence based platform for various insurances and for settling claims and paying premiums. The platform ensures transparency in issuing policies and settling disputes. The company is using technology, data, artificial intelligence, contemporary design, and social impact to deliver delightful and affordable insurances. The Company operates in one report segment providing personal property and casualty insurance products within the United States and Europe, including the UK.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.